Business Context and Reporting Period
Company: Semtech Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 30, 2006 (Second Quarter of Fiscal Year 2007)
Context: This filing is a restatement of previously reported financial data. Concurrent with this filing, Semtech filed an Amendment No. 1 to its 2006 Annual Report (Form 10-K/A) to correct accounting errors related to stock option grants made primarily between 1996 and 2003. The restatement adds approximately $91.0 million in pre-tax non-cash stock-based compensation expense. Prior financial statements issued before July 20, 2006, are superseded and should not be relied upon.
Key Financial Metrics
| Metric | Three Months Ended July 30, 2006 |
Three Months Ended July 31, 2005 (Restated) |
Six Months Ended July 30, 2006 |
Six Months Ended July 31, 2005 (Restated) |
|---|---|---|---|---|
| Net Sales | $64.9 million | $58.0 million | $130.9 million | $114.2 million |
| Gross Profit | $35.4 million (54.5% margin) | $32.1 million (55.3% margin) | $73.3 million (56.0% margin) | $63.7 million (55.8% margin) |
| Operating Income | $7.3 million | $9.0 million | $18.8 million | $20.3 million |
| Net Income | $8.4 million | $7.0 million | $20.2 million | $17.4 million |
| Diluted EPS | $0.11 | $0.09 | $0.27 | $0.23 |
| Cash & Equivalents | $100.8 million | (Balance Sheet Data) | ||
| Total Investments | $206.6 million | |||
| Working Capital | $307.3 million | (As of July 30, 2006) | ||
| Long-Term Debt | $0 | (As of July 30, 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% year-over-year for the quarter and 15% for the six-month period. Growth was driven by a 75% increase in sales to industrial, medical, and military markets and a doubling of sales to automated test equipment (ATE) markets, partially offset by declines in computer and cellular phone applications.
- Operating Expenses: Total operating costs and expenses increased 22% for the quarter and 26% for the six-month period. This increase was primarily due to the adoption of SFAS 123(R) (fair value accounting for stock-based compensation) and significant legal and professional fees related to the stock option investigation and restatement.
- Stock-Based Compensation: Pre-tax stock-based compensation expense was $523,000 for the quarter and $1.1 million for the six months ended July 30, 2006. This is a significant increase compared to the prior year due to the new accounting standard, though the restatement adjustments for the current period were immaterial.
- Acquisition Impact: The 2005 acquisition of XEMICS contributed to sales growth. The earn-out obligation of up to $16.0 million was not triggered as performance objectives were not met.
- Insurance Settlements: The company recorded a $3.0 million gain in the prior year quarter from insurance settlements related to a customer dispute, which is not present in the current period.
Outlook, Risks, and Management Commentary
- Restatement and Legal Proceedings: The company is facing five shareholder derivative lawsuits and government inquiries (SEC and Grand Jury) regarding historical stock option practices. Management expects to incur substantial legal and accounting fees for the foreseeable future. Approximately $2.3 million in such expenses were incurred in the second quarter of 2007.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of July 30, 2006, due to a material weakness in the control environment involving the Former CEO and Former CFO. Remediation efforts included the departure of implicated executives.
- NASDAQ Listing: The company faced potential delisting due to late filings but has stayed the process. Compliance is expected upon the filing of this restated report.
- Liquidity: The company maintains a strong liquidity position with $307.4 million in cash and investments. It has no long-term debt. Management believes cash flows and reserves are sufficient to fund operations and capital expenditures.
- Supply Chain Risks: The company relies heavily on foreign subcontractors, particularly in China (58% of silicon wafers), Malaysia, and the Philippines. Disruptions in these regions could materially impact operations.
Investor Verification Checklist
- Restatement Accuracy: Verify the $91.0 million pre-tax adjustment for stock option accounting errors and its impact on retained earnings and EPS.
- Legal Exposure: Monitor the status of the five shareholder derivative lawsuits and government inquiries regarding stock option improprieties.
- Internal Control Remediation: Confirm the effectiveness of new internal controls following the departure of the Former CEO and CFO.
- Stock Option Liability: Assess potential liabilities related to employees prohibited from exercising expiring options during the restatement process (accrued $2.1 million pre-tax in Q4 2007).
- Supply Chain Concentration: Evaluate risks associated with reliance on a single foundry in China for the majority of silicon wafers.